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Abstract
Pancreatic cystic lesions (PCLs) comprise various pathologically different groups of
lesions that usually share many common clinical  features.  Cystic lesions and fluid
collections  of  the  pancreas  often  present  a  diagnostic  and  therapeutic  challenge.
Pancreatic cystic lesions are being diagnosed with increasing frequency owing to the
widespread use of cross-sectional imaging. The differential diagnosis for cystic lesions
of the pancreas is broad, and the role of endoscopic ultrasonography (EUS) is becoming
more clearly defined. EUS has become an important tool in the diagnosis and risk
stratification of pancreatic cysts. The ability of EUS to provide detailed imaging, tissue,
and cyst fluid for analysis makes it a seemingly powerful diagnostic tool for PCLs. It
can  accurately  visualize  the  cyst  morphology,  assess  vascular  pattern  by  contrast
harmonic scan, and perform fine-needle aspiration (FNA) for evaluation of cytology
and  molecular  markers.  Furthermore,  several  studies  have  shown the  therapeutic
applications of endoscopic ultrasound in management of PCLs, including EUS-guided
ablation  of  cystic  pancreatic  tumors  by  injection  of  alcohol,  aiding  in  pancreatic
pseudocyst drainage.
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1. Introduction
Pancreatic cystic lesions (PCLs) are being diagnosed with increasing frequency, including a wide
spectrum from benign to malignant and invasive lesions. The most commonly observed PCL
types include intraductal papillary mucinous neoplasms (IPMN), mucinous cystic neoplasms
(MCN), serous cystic neoplasms (SCN), and pseudocysts (PC) [1, 2]. Differentiation of neoplastic
mucinous from non-mucinous cysts that are managed quite differently is important. If non-
mucinous pancreatic lesions such as inflammatory pseudocysts and neoplastic lesions are
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accurately characterized, most does not require resection or long-term follow-up. Mucinous
neoplasms have a known pre-malignant potential and, therefore, are either resected or monitored
in a surveillance program [3, 4].
Preoperative diagnosis of PCLs must be reliable as the current standard treatment, major or
total pancreatectomy, dramatically affects quality of life. Additionally, early diagnosis of
malignancy is essential to an improved prognosis. Despite being the most common modality
to identify cystic pancreatic lesions, cross-sectional imaging plays a variable role in character-
izing these lesions. Endoscopic ultrasonography (EUS) has become an important tool in the
diagnosis and risk stratification of pancreatic cysts [5–7].
EUS was first introduced by Dr. Eugene DiMagno in the 1980s by combining a high frequency
ultrasound transducer to an endoscope. In 1991, convex linear-array echoendoscope was
introduced by Pentax. These linear scopes scan parallel to the longitudinal axis of the scope
and enable fine-needle aspiration (FNA) and different therapeutic applications. EUS provides
real-time high-resolution images of cystic pancreatic lesions with morphological details [6, 8].
The combination of fine-needle aspiration (FNA) cytology with the other recently available
diagnostic markers has further increased its diagnostic accuracy. The current diagnostic
evaluation of PCL often includes EUS-guided fine-needle aspiration (EUS-FNA) for cyst fluid
analysis. In addition to the role of EUS in the differential diagnosis of pancreatic cystic lesions,
EUS-FNA is also important in management of cystic tumors of the pancreas [9, 10].
2. Diagnostic role of EUS
The critical issue being faced in routine clinical practice is accurate preoperative characteriza-
tion of cystic lesions. Histology remains the gold standard but requires resection. Since that is
impractical for most low risk lesions, imaging provides indirect evidence of morphology.
Pancreatic cysts can be diagnosed and assessed by using computer tomography (CT) and
magnetic resonance (MR), but these imaging modalities have been inconsistent in differenti-
ating them [3, 11]. CT scan, MRI, and MRCP are generally considered safe and reliable in
providing follow-up data on cyst and pancreatic duct size but are less sensitive in detecting
intra-mural nodules, which are better evaluated by EUS-FNA [6, 12]. The accuracy of MRI and
CT to make a specific diagnosis is suboptimal, with reports of 39–50 and 40–44%, respectively.
Efforts to differentiate pancreatic cystic lesions from imaging tests have met with mixed
success, with up to 40% of neoplastic cysts misdiagnosed as pseudocyst [3, 7]. EUS, particularly
as a means of EUS-guided cyst aspiration, has become an important tool in the diagnosis and
risk stratification of pancreatic cysts. The diagnostic accuracy of EUS for identification of
malignant or pre-malignant pancreatic cysts reaches 95%, although this method has significant
limitations for the differential diagnosis of benign and malignant cysts with overall accuracy
rates of 40–93% [7, 11].
The goal in assessing pancreatic cysts by EUS is to avoid characterizing a mucinous cyst as a
benign serous cyst and erroneously opting for simple observation instead of potentially curable
surgical resection. Endoscopic ultrasound is increasingly used for the differential diagnosis of
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pancreatic cystic lesions either alone or in combination with fine-needle aspiration. EUS allows
close and high-resolution imaging of cystic pancreatic lesion morphology. The appearances of
the cyst wall, the presence of septate or solid components, the number of cysts, and concomitant
lymphadenopathy have been used to distinguish between benign and malignant cystic
lesions [6, 13]. EUS-FNA has the added advantage of allowing aspiration of the cyst contents
and sampling of the cyst wall or septa, as well as mural nodules. Cyst fluid aspiration can be
more studied to analyze cytology, tumor markers, enzymes, as well as DNA analysis of DNA
quality/content or mutational analysis [9, 14].
2.1. EUS morphology
Some PCLs have a very typical morphology and may thus be easily diagnosed by imaging.
Diagnosis based on the findings of EUS requires attention to the number and size of cysts,
shapes of whole cysts, state of the cyst wall, internal state of the cysts, communication between
the pancreatic duct and the cyst, and existence of any background lesions (Table 1). It is
generally believed that a differential diagnosis is practicable partly by collating these findings
with the above features of the various pancreatic cystic lesions [15, 16].
Cyst type Location Morphology/EUS
findings
Fluid color
and viscosity
Cytology CEA1 Amylase
Mucinous
cystadenoma
Body/tail
more than
head
Macrocystic,
occasionally septated;
peripheral calcifications,
soli components and
regional adenopathy
when malignant
Colorless,
thick fluid
Extracellular mucin.
Mucinous epithelial
cells may be seen in a
background of
ovarian stroma
Moderate to
very high
Variable
IPMN2 Main duct or
side branch;
head more
than body
and tail
Dilated main pancreatic
duct or
side branches; may
appear as a septated
cyst; may have a
solid component
Colorless,
thick fluid
Extracellular mucin.
Mucinous epithelial
cells
may be seen with
papillary projections
and variable atypia
Moderate to
very high
Elevated
Serous
cystadenoma
Body/tail
more than
head
Microcystic with a
honeycomb appearance;
rarely
has a macrocystic
component; central
calcification
Colorless,
often
contain
blood
Typically acellular.
Small glycogen
staining  cuboidal
cells in the background
may be seen
Undetectable
to low
Low
Pseudocyst Anywhere Anechoic, thick-walled,
rare septa
tions, regional
inflammatory nodes may
be seen
Yellow to
brown thin
fluid
Macrophages with no
mucin. Mixed inflam
matory infiltrate may be
seen
Low to at
least increase
Elevated
1Carcinoembryonic antigen.
2Intraductal papillary mucinous neoplasm.
Table 1. Characteristics of cyst fluid in the main types of cystic pancreatic lesions [2, 6].
Several EUS findings have been evaluated to diagnose pancreatic cystic lesions. Studies have
shown that small cyst size does not exclude malignancy. Some features do appear to be more
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predictive in diagnosing specific types of cystic lesions. The existence of multiple small
compartments (<3 mm) within a cystic lesion (also called a microcystic lesion) is indicative of
a serous cystic neoplasm, with an accuracy of 92–96%, and this feature is not seen in mucinous
cystadenomas. A cystic lesion without septations or solid components and seen within a
pancreas having parenchymal features suggestive of a pseudocyst with sensitivity and
specificity of 94 and 85%, respectively. However, EUS morphology alone does not appear to
be very reliable to establish a specific diagnosis or to differentiate between benign and
malignant diseases (Figures 1 and 2) [2, 6, 7].
Figure 1. Main-duct intraductal papillary mucinous neoplasm (MD-IPMN): thick wall with mural nodules—by Prof.
Alizadeh.
Figure 2. Cyst fluid evaluation-EUS/FNA—by Prof. Alizadeh.
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2.2. Cyst fluid evaluation
EUS-FNA allows aspiration of the cyst contents and plays an important role in differential
diagnosis of doubtful cases of pancreatic cysts. Cyst fluid analysis is useful in differential
diagnosis between mucinous and non-mucinous pancreatic cystic tumors. Cystic fluid aspirate
is acellular or with minimal cellularity in up to 72% of aspirated cysts. Cyst fluid can be studied
after aspiration to analyze cytology, viscosity, extracellular mucin, tumor markers (CEA, CA
19-9, CA 153, Ca 72-4, etc.), enzymes (amylase, lipase), and DNA analysis. Analysis of cystic
fluid aspirate can be used to differentiate mucinous from non-mucinous cysts with a sensitivity,
specificity, and accuracy of 12.5–27, 90–100, and 55%, respectively [7, 17].
2.2.1. EUS-FNA with cyst fluid cytology
Due to the shortcomings of EUS alone, the use of EUS-FNA has been extensively evaluated for
fluid analysis and cytology of pancreatic cystic lesions. EUS-FNA cytology provides excellent
specificity (more than 90%) for the diagnosis of cystic pancreatic lesions. However, the
sensitivity of EUS-FNA remains widely variable with most studies reporting sensitivity under
50% [6, 7].
EUS-FNA can provide material for a cytologic diagnosis in up to 80% of cases of pancreatic
cystic lesions. Viscosity is usually lower in pseudocysts and serous cystadenomas when
compared with mucinous cystadenoma and mucinous cystadenocarcinoma. Furthermore, the
presence of extracellular mucin in aspirated cyst fluid is moderately predictive of a mucinous
neoplasm. Findings suggestive of a pseudocyst include macrophages, histiocytes, and
neutrophils. The presence of mucin indicates a mucinous neoplasm and is seen in 35% or more
of cases. FNA from a minority of serous cystadenoma may reveal the presence of glycogen-
rich cuboidal cells (Table 1) [2, 11, 18].
2.2.2. Cystic fluid analysis and tumor markers
Because of the limited sensitivity of cytology, cyst fluid may be analyzed for levels of amylase,
lipase, and tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen
(CA) 19-9. Early studies in the 1980s suggested the role of CEA and CA 19-9 in the differen-
tiation of pancreatic cystic lesions [9, 18].
Cyst fluid contains glycoproteins, such as CEA, CA 19-9, CA 125, CA 15-3, and CA 72-4,
which are secreted from the epithelial lining. CEA is currently considered the most reliable
for the diagnosis of mucinous cystic pancreatic lesions. This marker is typically elevated in
mucinous lesions but is lower in pseudocysts and non-mucinous tumors [6, 7]. CA 19-9 also
has wide overlapping of results with pseudocysts and serous cystadenomas. Furthermore,
other markers such as amylase and lipase may be important in the evaluation of cystic pan-
creatic lesions. Amylase is useful in the differentiation of pseudocysts from cystic neoplasm
and usually elevated not only in inflammatory cysts like pseudocysts but also in mucinous
neoplasm due to communication with the pancreatic duct (Table 2) [6, 9, 13].
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Cyst Viscosity Amylase CA 72-4 CEA CA 15-3 CA 19-9
Pseudocyst Low High Low Low Low Low
Serous cystadenoma Low Variable Low Low Low Low
Mucinous cystadenoma Often high Variable Low High High High
Mucinous cystadenocarcinoma High Variable High High High High
Table 2. Cyst fluid analysis for differentiation of pancreatic cystic lesions [19].
2.2.3. Cystic fluid analysis and genetic markers
Another differential diagnosis of pancreatic cystic lesions is DNA and mutational analysis in
the cystic fluid aspirated by EUS-FNA. Molecular analysis of pancreatic cyst aspirated fluid
may be helpful in predicting malignancy. The detection of loss of heterozygosity (LOH) by
using microsatellite markers closely linked to key tumor suppressor genes can serve as a
surrogate marker for gene inactivation and mutation [11, 18].
Molecular markers are greatly sought as a more reliable alternative diagnostic marker for many
malignancies, due to the revolution in translational science. Specific genetic markers are
increasingly identified and used to measure the risk of malignancy in pancreatic cystic lesions.
It is believed that IPMNs should follow a transformation process similar to the adenoma-
carcinoma sequence in colon cancer, where hyperplastic lesions progress to dysplastic and
carcinoma cells. Recently, the oncogene GNAS was detected in IPMN tissue. Some reports have
indicated that GNAS mutations are prevalent especially in the intestinal and invasive form of
IPMN. Furthermore, mutations in K-ras, p16, and p53 have been reported in associated with
progression of cystic pancreatic lesion from non-dysplastic to dysplastic cysts [6, 7, 18].
3. Therapeutic role of EUS
Management of incidentally detected pancreatic cysts with malignant potential is a common
clinical challenge. Surgical resection is the treatment of choice for most suspicious cystic lesions
of the pancreas [12, 19]. Surgical resection of pancreatic cyst is associated with a perioperative
morbidity rate of 20–40% and a mortality rate of 2%. EUS can be used to mark the optimal
puncture site or to perform EUS-guided cyst puncture and drainage. Moreover, EUS-guided
anti-tumor therapy may be applied to cystic pancreatic tumors, and early results of EUS-
guided alcohol injection into pancreatic cystic tumors were recently reported [2, 10, 19].
3.1. Endoscopic drainage
A pancreatic pseudocyst is the most common cystic lesion of the pancreas. Pseudocysts should
be drained when symptomatic, progressively enlarging, or infected. Pseudocysts have been
drained through stenting of the pancreatic duct (transpapillary drainage) or stenting of a
drainage tract created between the pseudocyst and the gastroduodenal lumen (transmural
drainage). Drainage can be achieved through endoscopic, radiologic, or surgical techniques.
Endoscopic drainage of pancreatic pseudocysts is less invasive than surgery [14, 20].
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Endoscopic methods for pancreatic pseudocyst drainage are associated with low mortality and
acceptable success rates. EUS-guided drainage is associated with a low rate of complications.
Prior to the availability of EUS, transmural endoscopic cyst drainage was reliant on a combi-
nation of radiologic imaging to ensure a distance of less than 10 mm between gastrointestinal
lumen and cyst. Endoscopic drainage may be performed as so-called single-step endo-
ultrasonography (EUS)-guided and two-(multi)-step EUS-guided drainage techniques [14,
17]. EUS has the theoretical advantage of reducing the risks of bleeding, perforation, and,
potentially, infection. Furthermore, this technique can provide important information in aiding
pancreatic pseudocyst drainage. It allows accurate measurement of the distance between the
gut lumen and the cystic cavity of the pseudocyst. EUS is helpful in identifying debris within
a pseudocyst, which may not be drainable and which may increase the risk of infection [21, 22].
3.2. EUS-guided pancreatic cyst ablation
EUS-guided pancreatic cyst ablation is practically an alternative treatment in selected patients
who are not candidates for or who refuse surgery. Based on the accumulated experiences of
endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA), EUS-guided pancre-
atic tissue ablation with ethanol or other ablative agents was performed safely, with few
procedure-related complications [12, 23]. Complications of cyst ablation were reported as rare
and mild. The most common acute complication was abdominal pain after cyst ablation (7.9%)
and acute pancreatitis developed in 2%. Although a novel technique such as radiofrequency
ablation was recently reported, it is still unclear whether or not cyst ablation is justified. Safety,
efficacy, and cost-effectiveness of EUS-guided pancreatic cyst ablation should be further
validated [7, 24].
To date, ethanol (80–99%) and paclitaxel have been investigated as ablative agents in pancreatic
cysts. A commonly used ablative agent is ethanol owing to its cost-effectiveness, ready
availability, and rapid ablative effect. The low viscosity of ethanol permits repeated filling and
emptying of the cyst [7, 23].
Ablation of the epithelial lining of a pancreatic cystic neoplasm has been proposed as a way
to reduce or eliminate malignant or metastatic potential in benign and malignant lesions,
respectively. Ethanol lavage of MCN and IPMN cystic lesions by using EUS guidance appears
to be safe, but its efficacy has not yet been determined. The mechanisms involved in destruction
of cyst epithelium include cell membrane lysis, rapid protein precipitation, and vascular
occlusion. Treatment response is further supported by adding a chemotherapeutic agent (most
commonly paclitaxel), which acts as an inhibitor of the disassembly process of microtubules
during cell division and subsequently inducing apoptosis [18, 25].
4. Conclusion
Pancreatic cystic lesions (PCLs) comprise a diverse group of histopathologic bodies possessing
varying degrees of malignancy. PCLs range from benign abnormalities needing minimal
follow-up to pre-malignant or malignant lesions requiring careful monitoring or resection. The
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diagnosis and management of pancreatic cystic lesions are a common problem. EUS and EUS-
guided fine-needle aspiration (FNA) can play an important role in the differential diagnosis
of pancreatic cystic lesions and decision about referral for possible surgery by evaluating
cytology and tumor markers. There is some emerging evidence that EUS-guided pancreatic
cyst ablation by injection of alcohol can help to treatment of the cystic pancreatic tumors.
Furthermore, EUS can provide important information in aiding pancreatic pseudocyst
drainage.
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